The deal size was reduced to $175M from $250M and priced below last closing price of $14.30. BofA, Evercore ISI, Goldman Sachs, Stifel and Wells Fargo are acting as joint book running managers for the offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Mineralys Therapeutics announces $250M common stock offering
- Buy Rating Affirmed for Mineralys Therapeutics, Inc. Due to Promising Lorundrostat Study Outcomes
- Promising Potential of Lorundrostat Drives Buy Rating for Mineralys Therapeutics, Inc.
- Mineralys Therapeutics Reports Positive Phase 3 Trial Results
- Mineralys Therapeutics announces results from Launch-HTN, Advance-HTN trials